Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma.
Document Type
Article
Publication Date
3-1-2024
Abstract
Anaplastic lymphoma kinase ( ALK )-fusion sarcomas are rare part of the emerging theoretically targetable tyrosine kinase RAS::MAPK pathway fusion myopericytic-ovoid sarcomas. We report our clinicopathologic and treatment experience with an ALK fusion sarcoma. A novel ELKS/RAB6-interacting/CAST family member 1 - unaligned ALK fusion infiltrative nonmetastatic low-grade sarcoma of the right hand of a 15-month-old male was treated with crizotinib, an ALK tyrosine kinase inhibitor as oral monotherapy, inducing complete radiographic and clinical resolution by 10 months and sustained response now over 12 months after elective discontinuation. Crizotinib can successfully be used to treat unresectable novel ALK fusion sarcomas.
Publication Title
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology
Volume
46
Issue
2
First Page
e184
Last Page
e187
Recommended Citation
Wood, M., Fanburg-Smith, J., Brian, J., White, J., Powell, J., & Freiberg, A. (2024). Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma.. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology, 46 (2), e184-e187. https://doi.org/https://doi.org/10.1097/mph.0000000000002777